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Illuminating the Coronavirus 
Enlightening our minds, and relaxing 
our thoughts.  
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Letter from the Editor 
A Big Thanks from our Executive Team! 
Editor-in-chief: Anthony Isenhour 
Associate Editor: Joseph McEachon 
Managerial Editor: Cassidy Hilton 
PR and Social Media: George Qiao 
Good luck to upcoming executive team! 
Ryan Shah, Lily Dickson, Ryan Cvelbar, and Caterina Erdas 
Dear Readers, 
We thank you for supporting us as this 
is our 8th issue of Osmosis! Even in 
times as rough as these, I’ve been 
proud to work with a team of editors, 
writers, and designers who have been 
willing to continue talking about sci-
ence. I hope you enjoy this issue and 
take it as an opportunity to read about 
some fun science. I wish the future 
teams on Osmosis the best of luck and 
I know you’ll do us proud! 
As always, Science on! 
Anthony Isenhour 
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 Biological weapons, as defined by the Federa-
tion of American Scientists, are “toxins and microor-
ganisms, such as viruses and bacteria, used to deliber-
ately inflict disease among people, animals and agri-
culture.”
1
Biological weapons have 
been used for hundreds of years on 
varying scales, from the catapulting 
of plague-infected corpses into ene-
my cities in the 14th century, to the 
testing of infectious diseases in Chi-
na during WWII, to the 2001 an-
thrax attacks. These weapons act 
discreetly, as it is hard to trace an 
outbreak to a particular attacker and 
it takes several days for an infected 
individual to show signs of the disease. Moreover, be-
cause biological weapons are often highly infectious, 
their effect on society is far reaching. While state ac-
tors have made use of biological weapons in the past, 
the discreet and wide-reaching aspects of biological 
weapons make them increasingly appealing for terror-
ist groups, as they have the capability to disrupt socie-
ty and cause panic. 
 A biological weapon can be developed in three 
steps—selecting a pathogen, growing and developing 
the microorganism, and preparing the disease for de-
livery. When selecting the pathogen, the designers of 
the weapon must consider how the biological agent 
spreads, how long it incubates, and how destructive it 
is. Generally, weapon developers aim to use biological 
agents that are highly contagious and have relatively 
short incubation periods, high mortality rates, and the 
potential to cause public panic. Some agents that fit 
these characteristics, and are hence popular choices for 
biological weapons, include anthrax and 
the plague.
2
 Anthrax is the bacteria Bacil-
lus anthracis, and it traditionally infects 
people who work with animals, but it can 
also be spread through aerosol. Gastroin-
testinal anthrax has a mortality rate of 25-
75%, while inhaled anthrax can have a 
mortality rate of over 80%.
3
 Another 
common pathogen used as a biological 
weapon, Yersinia pestis( plague) is a bac-
teria that causes painful, swollen lymph 
nodes, fever and extreme exhaustion. Though out-
breaks traditionally began with rat-to-human transmis-
sion, plague bacteria can also be released through aer-
osol, and the infection easily spreads from person to 
person. Plague mortality rate is around 50%.
3 
Both of 
these diseases are commonly used as biological weap-
ons because of their ease of spread and high mortality 
rates. Scientists can obtain these biological agents 
from the environment, but they are more commonly 
acquired from pathogen banks. Individuals also donate 
samples of the pathogen, which scientists can genet-
ically modify into a biological weapon.
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 After choosing and acquiring the biological 
agent, scientists use genetic engineering technology to 
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alter the pathogen to be more resilient and lethal. Us-
ing gene editing technology, scientists can change the 
genetic material of pathogens by either inserting 
genes, deleting genes, or altering existing genes to 
produce pathogens with desired traits. Bacterial agents 
may also be altered to be resistant to antibiotics, 
which makes infections resulting from these bacteria 
difficult to treat.
4
 This biotechnology is expensive, 
however, and acquiring it is a hurdle for groups at-
tempting to develop effective biological weapons.  
 Once the pathogen is edited, scientists must 
choose a method of delivery. The most common meth-
ods of spreading biological weapons are through the 
air using bombs or sprays, through the water supply, 
and through the food supply. The Japanese commonly 
used aerosol pathogens in their tests on China in 
World War II, and there are documented instances of 
salmonella and E. coli being deliberately added to 
food, such as salad bars.
5 
The chosen method of trans-
mission will depend on how widespread or controlled 
the attack is intended to be.  
 International treaties have been implemented 
to slow or prevent the development of biological 
weapons. The 1925 Geneva Protocol banned use of 
biological weapons in warfare, and the 1972 Biologi-
cal and Toxin Weapons Convention (BTWC) went a 
step further to prevent development, production, 
stockpiling, and acquisition of biological weapons.
1 
However, it is nearly impossible to make sure that 
countries follow these treaties, and underground bio-
logical weapon programs continued, even in signatory 
countries. For example, the Soviet Union signed the 
BTWC but then started Biopreparat, a well-funded 
biological warfare research project. Through the pro-
gram, the Soviet Union stockpiled anthrax bacteria 
and smallpox viruses undetected until the program’s 
dissolution in 1992.
5
 In addition to non-compliance in 
state actors, non-state actors have made use of biologi-
cal weapons. The anthrax attacks of 2001 were carried 
out by a non-state actor, as was the spread of salmo-
nella through salad bars by a religious sect in the 
1990s.
5
 The ease of access to biological agents makes 
bioterrorism, the use of biological weapons by a non-
state actor to reach a political goal, a real and growing 
threat.  
 What can be done to combat the threat of bio-
terrorism? Perhaps the most important step is being 
prepared for an attack. The U.S. can invest in stockpil-
ing vaccines for diseases like anthrax and the plague, 
researching possible new pathogens that could be used 
as biological weapons, and modeling possible out-
comes of a biological attack. We can use what we 
know about the development of biological weapons to 
learn how to best protect ourselves from them, 
through modeling various diseases in different formats 
and mutations, and using these models to form plans 
to combat these pathogens. Additionally, there is the 
growing field of bioterrorism forensics, which aims to 
use DNA evidence to identify pathogens that could be 
developed into biological weapons.
6 
While it is im-
possible to predict the exact timing and details of an 
attack, it is possible to prepare for possible attacks. 
Additionally, good hygiene practices, such as washing 
hands and staying up to date in vaccinations, can help 
individuals avoid contracting illnesses released by bi-
ological weapons. The threat posed by biological 
weapons and bioterrorism is present and growing, but 
there are measures that can be taken to protect us from 
a deadly attack.  
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For 40 years of her life, Edi Guyton could not experi-
ence happiness. Despite having a family and a suc-
cessful career, she still struggled to feel happy. She 
tried various therapies and medications, but to no 
avail. Then, in 2007, Edi Guyton underwent an experi-
mental procedure that allowed her to smile genuinely 
for the first time in her life. Due to two electrodes 
implanted in her brain and a small battery pack near 
her collar bone, Edi is now able to experience the joys 
of life like everyone else.10 Deep brain stimulation 
(DBS), the process of implanting electrodes into the 
brain to lessen the symptoms of neurological diseas-
es, began as an experimental idea based on early 
pain-processing theories. Today, DBS is used to treat 
various neurological disorders, including Parkinson’s 
disease, depression, OCD, and chronic pain. While 
major advancements have been made in recent 
years, DBS is still in its infancy and possesses a tre-
mendous potential to advance human well-being as 
our knowledge of neuroscience increases. 
The History of Deep Brain Stimulation 
The discovery of deep brain stimulation began in 
1965 when Ronald Melzak and Patrick Wall proposed 
their gate-control theory of pain. Through their stud-
ies, Melzak and Wall discovered that nerve fibers that 
transmit information about touch and vibration are 
more myelinated, and therefore faster acting than 
nerve fibers that transmit pain signals. In the dorsal 
horn of the spinal cord, these fast-acting nerve fibers 
can inhibit pain signals from reaching the brain. The 
gate-control theory explains why we tend to rub our 
head when we hit it on a doorframe or grab our foot 
when we step on a Lego. Increasing touch signals 
helps inhibit pain.3 
The gate-control theory of pain gave rise to ideas 
about how pain can be controlled from a bottom-up 
process, in which pain signals are processed via the 
spinal cord before reaching the brain. Then, in 1969, 
D.V. Reynolds discovered a top-down process in 
which the brain receives pain signals first and pro-
ceeds to inhibit them. In his study, Reynolds stimulat-
ed the periaqueductal gray regions in the midbrain of 
rats and performed surgery on them without anes-
thesia. The rats felt no pain for the duration of the 
surgery.3 This phenomenon occurs because the peri-
aqueductal gray region has associations with nerve 
fibers that send signals to the dorsal horn of the spi-
nal cord, the same area where pain is inhibited during 
gate-control.2 Reynold’s study demonstrated that the 
brain also has the ability to inhibit pain. 
With the knowledge that pain can be inhibited from 
the spinal cord or from the midbrain, researchers 
attempted to cure chronic pain using two approach-
es. The first approach is spinal cord stimulation, 
which involves placing electrodes in the spinal cord to 
generate a pulse to keep pain signals from reaching 
the brain. This method of treating pain was originally 
believed to work due to gate-control theory, but cur-
rently research has shown that there may be more 
factors at play. Essentially, the added electrical sig-
nals from the electrodes inhibit the pain signals from 
reaching the brain.5 As a result of its success, spinal 
cord stimulation was FDA approved and used as a 
method for pain relief.3 
The second method used to cure chronic pain was 
DBS, which was originally proposed in the 1970s. 
Electrodes were placed in the thalamus, the part of 
the brain responsible for directing pain signals for the 
somatosensory cortex for processing. Unfortunately, 
clinical trials did not produce convincing evidence for 
the effectiveness of DBS.3 Today, we know this is be-
cause the original trials were poorly executed,4 but at 
the time, it appeared DBS had reached an end.  
Brains on Batteries: The Potential of 
Deep Brain Stimulation 
By Joshua Pandian 
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 DBS seemed to be a failed idea until the 1980s, when 
it was found to be effective in countering motor 
symptoms associated with Parkinson’s disease.3 In-
creased knowledge of the brain regions associated 
with Parkinson’s disease allowed scientists to better 
target areas to stimulate to help counter irregular 
activity. Even today, our knowledge of these brain 
regions continues to expand. For instance, a 2018 
study on the interactions between the basal ganglia 
and thalamus revealed that in low dopamine envi-
ronments, inhibitory output from the basal ganglia 
can cause rebound firing in the thalamus, leading to 
motor symptoms associated with Parkinson’s dis-
ease.6 Modulating basal ganglia output or the re-
bound firing can help eliminate involuntary muscle 
contractions, so DBS can potentially be the answer to 
this problem.  
Where is DBS Today? 
After DBS was first approved in 1997, the applica-
tions of it have expanded beyond Parkinson’s dis-
ease. One example of this is the use of DBS to treat 
certain types of depression. In 2005, Dr. Helen May-
berg used DBS on Brodmann area 25, a part of the 
brain that has been identified as overactive in indi-
viduals with treatment resistant depression. Accord-
ing to the study, stimulating this region with elec-
trodes can help decrease activity in the region, which 
in turn affects the hypothalamus and the brainstem. 
For patients receiving this treatment, this means 
better sleep, motivation, and energy. As this study 
shows, DBS is effective because it modulates multiple 
functions in the brain by changing processes in the 
target site and downstream.7 
Patients suffering from obsessive compulsive disor-
der (OCD) may also be able to benefit from DBS.  A 
recent study showed that targeting one of five possi-
ble brain areas can relieve OCD symptoms. However, 
it appears that stimulating the different regions have 
different impacts on the brain, so a more personal-
ized approach must be taken to provide the appro-
priate treatment to each patient.8 
Advances in using personalized DBS techniques have 
led researchers to again attempt combating chronic 
pain with DBS. Dr. Shirvalkar, an associate professor 
of anesthesiology at UC San Francisco, is using the 
technology available today to monitor neural activity 
over time in order to create DBS with varying electri-
cal pulses depending on the situation.9 Studies such 
as these show promise for DBS to be more accurate 
and effective in the future. 
What still needs to be done? 
Although DBS is becoming more effective over time, 
there is still plenty of room for improvement. One of 
the biggest challenges facing the advancement of 
DBS is the current lack of understanding about how 
certain brain functions interact. While research can 
often get general ideas for what different brain re-
gions do, it is still difficult to target which area to 
place the electrodes in order to have effective DBS. 
This is seen from the studies of DBS on OCD, where 
treatments of multiple brain regions appear to ease 
symptoms, but in different ways.8 Also, in some cas-
es, a patient’s brain can become used to the deep 
brain stimulation, thus rendering the treatment in-
effective. More research must be done in order to 
understand why DBS may cease to work in some pa-
tients.1 As research on the topic expands, patients 
will benefit from having DBS that is more personal-
ized and effective in treating their specific condition. 
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 The term coronavirus refers not to the newest, mysterious disease that is 
slowly spreading globally, but rather a family of viruses. These viruses are the 
source behind common illnesses such as the common cold to the more recent 
outbreaks of the coronavirus disease 2019 (COVID-19). Other more severe dis-
eases have occurred before then such as the Severe Acute Respiratory Syndrome 
(SARS) in 2003 and Middle East Respiratory Syndrome (MERS) in 2012. How-
ever, both had a combined number of only 29 cases in the United 
States.4Coronaviruses are animal-borne diseases meaning they begin as diseases 
in mammals or birds. Although animal-borne viruses are usually not able to 
transfer to humans, a virus can mutate allowing it to be transmitted to humans. 
Once transmitted to humans, the coronavirus often causes an upper respiratory 
infection with mild symptoms, but certain types such as MERS and SARS will 
have more severe symptoms.2  
What is the coronavirus?  
 COVID-19was first discovered in the Huanan Seafood 
Wholesale Market in Wuhan, China, in December of 2019.1,2The 
Huanan Seafood Wholesale Market is a wet market where live ani-
mals are bought and sold. Through the close proximity of the animals 
and humans, the virus would have been able to jump from animals to 
humans. While the disease is believed to have originated from the 
bats, pangolins -an armored nocturnal mammal -are believed to act as 
an intermediary before passing over to humans.3Studies into past 
coronaviruses have found similar transmittance with SARS being 
transmitted from civet cats to humans and MERS being transmitted 
from dromedary camels to humans.1  
How did it originate?  
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Coronavirus is spreading fast,  
but what is spreading faster?  
By Dana Morcillo 
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How does it spread and what 
are the symptoms?  
 Due to the novelty of COVID-19, how it spreads is mostly based on previous 
coronaviruses such as the common cold, SARS and MERS. There are two believed 
paths in which transmission for COVID-19 occurs: person-to-person and contact with 
infected surfaces and objects. Person-to-person transmission is the most likely route 
according to the CDC.2This can happen through close contact within 6 feet or coughing 
and sneezing which produces infective respiratory droplets. Contact through infected 
surfaces and objects is a less likely route. It occurs through an individual touching an 
area with the virus present and then touching their mouth, nose, or eyes.2 
 If infected, symptoms may appear between 2 to 14 days after exposure. A mild 
infection includes symptoms of fever, cough, and shortness of breath or difficulty 
breathing. A severe infection leads to severe illnesses suchas pneumonia.1,2Moreover, 
it’s believed that infected individuals are most contagious when they exhibit the most 
symptoms or are most sick. However, it’s possible for individuals to still spread the 
coronavirus without showing symptoms, but this isn’t believed to be the main way the 
disease is spreading.2  
  Stigmas. COVID-19 is the official name used by the CDC, but often -and even now -the virus was referred to 
as the “Wuhan virus” or the “China Virus.” While COVID-19 did originate in Wuhan, China, the words and language used when 
speaking about the virus are important. They carry power. More importantly, they carry the power to hurt. Globally, there has 
been an increase in xenophobic and overall, racist attacks. In Australia, parents refused to let their children be treated by Asian 
doctors.5 In Canada, a petition was formed and signed by over 10,000 residents to track and name Chinese-American students 
after any travel to China.6 In America, Chinese restaurants are struggling to stay afloat after business has gone down and racist 
attacks have been seen on public transits from the West to East Coast.7 A survey by the Asian Pacific Policy & Planning Coun-
cil (A3PCON) has received over 1,100 reports of racist attacks from being coughed or spat at to physical assault.8 However, 
these racist attacks don’t only affect Asians and Asian Americans but other minorities as well. 
 While the CDC has officially recommended that all Americans wear face masks, minorities are afraid of the larger im-
plications at hand.9 Historically, bandanas when worn by Hispanics or African Americans have been strongly associated with 
gang involvement and violence. The worry then becomes that minorities wearing masks made of bandanas or other materials 
will be stereotyped and targeted. The most recent instance being two African American men who claim to have been escorted 
out of Walmart for wearing masks.10  
 Going forward, it’s important that all individuals feel safe and accepted during such a fearful time. COVID-19 does not 
discriminate. All individuals are susceptible to it, especially our medical and essential workers. While we can do our duty of 
social distancing and staying at home to protect others, we also have a greater duty. To speak accurately and empathetically 
when it comes to COVID-19 and those affected by it. By knowing and understanding the facts can every individual prevent the 
spread of stigmas and hate, but instead foster compassion and understanding. 
7. Escobar, Natalie. (2020, March 4). When Xenophobia Spreads Like A Virus.
  Retrieved from https://www.npr.org/2020/03/02/811363404/when-
 xenophobia-spreads-like-a-virus  
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 wp-content/uploads/A3PCON_Public_Weekly_Report_3.pdf 
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 ing the Use of Cloth Face Coverings, Especially in Areas of Signifi
 cant Community-Based Transmission. Retrieved from https://
 www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-
 cover.html 
10. Melendez, Lyanne. (2020, April 9). Coronavirus help: Berkeley-based pro
 gram to distribute medical masks to African American, Latino com
 munities https://abc7news.com/coronavirus-bay-area-lockdown-
 shelter-in-place-update-california-covid-cases/6090822/  
So, what is spreading faster than coronavirus? 
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I  barely felt the cold, dry Montana air pierce my lungs as I looked through my scope for an icon-
ic animal in our culture: a wolf. While the dramatic 
thermal features on the south side of Yellowstone 
National Park attract the most visitors, the north is 
quiet and rich with life. The Lamar Valley is a stun-
ning stage for Yellowstone’s wildlife to interact 
with one another. As the sun rises and hits the 
mountain tops, the cold air rushes into the valley and 
creates a thick fog, a curtain. Backstage, the wooded 
mountain ranges slowly bleed into the tall grasses 
and sage bushes blanketing the valley ground. Final-
ly, I saw a black wolf’s head peeking above the tall 
grass. Another five followed, probably from the 
Junction Butte Pack who currently hold control over 
the Lamar Valley.  
By the 1920s, wolf populations were com-
pletely culled at Yellowstone National Park (YNP) 
by park officials and licensed hunters trying to pro-
tect their prime attractions: elk and other big-game 
animals. Wolves are the number one natural preda-
tor of elks, and at the time, there was concern that 
wolves were a danger to big-game animals. Howev-
er, after the wolves were removed, park officials and 
scientists started to notice over-grazing on young 
trees, rampant erosion, and unstable growth/crash 
cycles in elk populations. Therefore, in 1995, 
wolves from Canada were brought into YNP to bal-
ance the ecosystem.  To what extent wolf re-
introduction “saved” the greater Yellowstone eco-
system remains debated, but elk levels stabilized 
after re-introduction and by extension, the rest of the 
ecosystem stabilized. One hundred years later, seven 
generations of wolves have lived in Yellowstone 
and the surrounding area. That’s seven generations 
of wolf packs fighting to expand their territory, win-
ning, defending, losing, and dissolving as new packs 
grow (yes, it’s Game of Thrones with wolves). 
YNP’s wolf sanctuary provides a unique opportunity 
to study wolf behavior and biology, wolf pack dyn-
asties, and their effects on the local ecosystem.  
Apart from their own pack, wolves interact 
with ravens more than any other animal. The ravens 
are the most obvious beneficiary from the wolf-
raven relationship. Studies have found that 100% of 
wolf kills are visited by ravens and nearly 2/3 of the 
carcass is consumed by the raven. The official term 
for their relationship is predator-scavenger interspe-
cific kleptoparasitism, or, in English, a relationship 
between two different species where the scavenger 
benefits off the predator by stealing a portion of 
their food. The ravens stay close, recognize a wolf’s 
hunting cry, and follow the hunt from above. Ravens 
cannot open a carcass on their own, so without the 
wolves’ help, the eyes are the only edible part of the 
carcass for a raven. In this instance, the wolf is the 
predator being taken advantage of by the raven. 
However, wolf and raven behavior doesn’t 
perfectly fit the kleptoparasitism model. After a kill, 
wolves will only eat their preferred cuts of the meat 
and ignore the ravens and other scavengers pecking 
at the opened carcass by their side. If this were truly 
a competitive or parasitic relationship, the wolves 
Wolves and Ravens: Defining a unique relationship 
By Caterina Erdas 
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would protect their meal like they often do against 
bears. Even more counter intuitive, ravens are scared 
or “shy” of large carcasses and won’t feed on them 
unless a wolf is nearby. In addition. though wolves 
were gone from YNP for 70 years, ravens preferen-
tially follow wolves significantly over coyotes or 
elk. If ravens were solely opportunistic, then a raven 
would choose a carcass without a wolf and would be 
equally likely to follow coyotes. These odd behav-
iors hint at an innate, ancient, and evolved mutualis-
tic, not parasitic, relationship between wolves and 
ravens. 
Wolves obviously don’t mind ravens and 
have evolved with ravens, so what are they wolves 
getting out of their relationship? When wolves and 
ravens are preoccupied with feeding, the ravens re-
main extremely alert and will call out if danger is 
near. The ravens act as another set of eyes and ears, 
not only at a carcass, but in the sky. Ravens have on 
multiple occasions been observed locating, harass-
ing, and yelling at injured elk to draw the attention 
of wolves.  
Furthermore, there are numerous wolf-raven 
anecdotes that illustrate their special relationship. 
For example, a biologist studying wolves wrote 
about an interaction he saw of a raven pecking at the 
tail of a wolf and jumping away when the annoyed 
wolf snapped back in retaliation. A wildlife photog-
rapher saw a nearby wolf open up a bear carcass for 
a yelling raven who found the body. One wolf 
watcher noticed that ravens hang around wolf dens 
and play with three-week-old wolf cubs. Both ravens 
and wolves have the social abilities to form bonds 
between individual ravens and individual wolves. I 
have my own anecdote. Soon after spotting the 
wolves, I saw a raven. At first it was circling close 
above, but then it swooped down towards a wolf, 
taunting it. The wolf, in turn, jumped up and snapped 
its teeth at a safe distance from the raven. They re-
peated this dance a couple times. What at first 
looked like an aggressive interaction was actually 
two friends, playing. Watching the wolf and raven’s 
unique relationship play out in the Lamar Valley is a 
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G 
etting a hangover after drinking the night be-
fore can lead to varying regrets the next 
morning depending on a variety of factors 
including gender, weight, food consumption, and alcohol 
consumption. What a hangover feels like can vary a lot 
too: headaches, nausea, fatigue, etc.  
 Scientists are interested in understanding hango-
vers and how to prevent them because they experience 
them too. In order to better understand hangovers from 
a scientific perspective, a unifying definition needed to 
be set. In 2016, some scientists worked with consumer 
descriptions and experts to define a hangover from alco-
hol as referring “to the combination of mental and physi-
cal symptoms, experienced the day after a single episode 
of heavy drinking, starting when blood alcohol concen-
tration approaches zero.”1 Nonethelss, scientists are still 
confused about how hangovers work, and why only 
about 75% of people report having ever experienced a 
hangover.2 
` There are a variety of potential factors that 
affect hangovers, stemming from how the body breaks 
down the alcohol, to other chemicals in the drinks, as 
well as genetics and personal factors. Studies have 
shown that some metabolic pathways other than just 
breaking down the alcohol (ethanol) seem to be involved 
in hangovers and involve molecules like vitamin B6, zinc, 
and antidiuretics (which control how much water your 
body holds).3 Similarly, drinks like red wine, rum, and 
whiskey have more of the other chemicals that may 
make hangovers more severe such as methanol.4 
 However, in delving into the personal and ge-
netic factors that contribute to hangovers, studies have 
found that the sons of alcoholic parents (who are at 
greater risk for alcoholism) have more frequent hango-
vers.5 This could stem from genetic factors, as well as 
environmental factors affecting diet and approach to 
alcohol consumption. Similarly, scientists have seen that 
guilt about drinking and higher levels of anger or depres-
sion are associated with experiencing more hangovers.6 
Stress has been shown to bring on similar symptoms to 
hangovers and the scientists who saw the above emo-
tional ties to hangovers believe that this combination of 
different types of stress may be what is causing more 
hangovers. So if you’re getting ready for a night out to 
relieve some stress, be wary of how you might feel the 
next morning. 
 Not only do all of these factors contribute to 
hangovers, but it is found that gender does as well. Re-
search shows that women reach a higher blood alcohol 
content (BAC) with the same amount of alcohol, but that 
men typically consume more alcohol in a single drinking 
session leading to typically higher negative consequenc-
What’s the Hang-Up on Hangovers? 
By Anthony Isenhour 
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es. When studies take all of these factors into account, it 
seems that men are less sensitive to the adverse effects 
of alcohol (aka hangover symptoms) at the same BAC.7 
However other studies find that there are little to no 
differences between men and women in regards to hang-
overs so no one is safe.8,9  On another surprisingly posi-
tive note, a large-scale research project has found that 
hangover symptoms and severity tend to decrease as you 
age.10  
 While the likelihood that we may experience 
hangovers is clearly very variable, what about treating 
hangovers? A 2005 study compared a range of potential 
hangover cures--such as some various drugs, sugar, pick-
led vegetables, and fruits--only to find that none of them 
are effective hangover cures. However, a more recent 
study has shown that a diet rich in zinc and vitamin B3 
leads to less severe hangovers.11  Both of these seem to 
be important in helping regulate the proteins in your cells 
that are breaking down the alcohol. This study did also 
mention that for the 20-25% of people lucky enough to 
experience no hangover symptoms there must be some 
other biological reason. Similar to popular belief though, 
clear alcohols and ones that are closest to pure ethanol 
are less likely to promote hangovers.  
Scientists seem to conclude that a true hangover 
cure might be out there, but that traditional methods of 
moderation, diet, and basic symptom treatments are 
your best bet. Similarly, studies have not been able to 
identify a main cause for hangovers (other than drinking 
alcohol) that could help lead to lessening hangover sever-
ity. Instead, much like the rest of life, the pain comes 
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Tree Man Syndrome 
By George Qiao 
 Imagine a condition in which lesions that grow on your appendages are so severe that you cannot 
use your hands and feet properly. Moreover, these lesions are large and painful, and prevent you from being 
able to perform daily activities. Surgery, a common answer for this condition, can temporarily control the 
growths, but the lesions continue to grow back after each surgical operation. Currently, there is no cure, and 
the treatments only offer a temporary fix. Therefore, you are faced with a lifelong condition that severely 
limits your ability to live a normal life. Though there are many debilitating diseases, few of them are not 
given much attention. For example, one extremely rare disease is Epidermodysplasia verruciformis (EV), or 
tree man syndrome, characterized by bark-like warts growing on the body.1 Although the exact number of 
cases of EV is uncertain, about 200 cases in the world have been reported thus far.2 
 Discovered in 1922, EV is an autosomal recessive disorder that increases one’s susceptibility to the 
human papilloma virus (HPV) and is characterized by lesions that resemble wood. Furthermore, EV in-
creases one’s risk of developing skin cancer.3  HPVs are non-enveloped, double-stranded DNA viruses re-
sponsible for many lesions and cancers, and are often sexually transmitted.4 They infect the stratified epi-
thelium of the epidermis, and do not lead to symptoms for most individuals, although some cases can in-
volve development of warts. For infected individuals who show symptoms but are not suffering from EV, 
the warts are not as vast in number as those in patients with the mutations associated with EV.5 
 Researchers have generally attributed EV to mutations in the EVER1 and EVER2 genes, also 
called TMC6 and TMC8, respectively. These genes code for transmembrane proteins of keratinocytes, 
which are epidermal cells targeted by HPV. The proteins bind to and form a complex with a zinc transporter 
protein called zinc transporter 1 (ZnT-1). The EVER-ZnT complex transports zinc from the cytoplasm into 
the endoplasmic reticulum of the cell, directly decreasing the amount of zinc in the cytoplasm and indirectly 
decreasing the amount of zinc in the nucleus.5,6  Zinc is an ion vital for the function of AP-1 transcription 
factors which promote expression of the HPV genome. The EVER-ZnT complex limits the activity of AP-1 
transcription factors by decreasing the concentration of zinc in the nucleus, thereby limiting the ability of 
HPV to replicate.7 A mutation in either of the genes EVER1 or EVER2 would prevent the proper function-
ing of the EVER-ZnT complex and allow the proliferation of HPV. With the mutation, HPV infection can 
lead to uncontrolled division of keratinocytes, resulting in bark-like warts, especially on the hands and feet.1 
Immunohistochemistry with antibodies specific for HPV can detect HPV infection in keratinocytes and is 
used to diagnose patients with EV.2 
 Several treatments exist to combat EV, although there still remains no cure. The condition can be 
treated with surgery, which can remove the growths. However, surgery only offers a temporary solution to 
the condition, as the warts often return after surgery. One man in Bangladesh suffering from EV underwent 
multiple surgical operations to remove his warts in 2016. Although the surgeries granted him the ability to 
use his hands and feet for a period of time, the warts returned. Since 2016, he has had 25 surgeries, and has 
not found a permanent solution to the condition.8,9 Other treatments include cryotherapy, interferons, and 
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retinoids, all of which also offer temporary solutions to the problem.9, 10  
 Further research on EV should be conducted so that the scientific community can come closer to a 
cure for this debilitating disease. One path to take is to determine different possible causes of EV. Despite the 
experiments performed to determine the role of the EVER genes, it is not certain that a mutation in these 
genes is the sole cause of EV. In a particular study involving 41 EV patients, mutations in the EVER genes 
were present in 75 percent of the patients but absent in the remaining 25 percent, suggesting that there are 
other possible causes of EV.6 Thus, more research should be conducted to identify alternative causes of the 
condition. If we can determine the different mechanisms of action of this disease, we can come closer to a 
cure by directly targeting those mechanisms. Hopefully, in the future, we can find a solution that can help 
end the suffering of those affected by the disease.  
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CareCloud, a privately held technology com-
pany headquartered out of Miami, states that accord-
ing to recent figures, the average cost of an organ 
transplant in the U.S. can reach well over $1 mil-
lion. Furthermore, according to the United Network 
for Organ Sharing (UNOS), more than 113,000 pa-
tients in the U.S. are currently waiting for an organ 
transplant. Anne Paschke of UNOS stresses this need 
for organs by expressing that only 1 to 2 percent of 
the population dies in a way that 
makes them potential organ donors. 
Although the need for organs has yet 
to be met, bioprinting has the poten-
tial of saving lives by addressing this 
chronic shortage through various ap-
plications. 
Many of you may have heard 
of 3-D printing, but have you heard 
of bioprinting? Bioprinting is a bio-
technology that does not fail to excite 
optimists in the biotech industry. 
Specifically, bioprinting is “an addi-
tive manufacturing process where 
biomaterials such as hydrogels or 
other polymers are combined with cells and growth 
factors, and then printed to create tissue-like struc-
tures that imitate natural tissues” (What). You may be 
wondering how exactly this printing process takes 
place. Futurity explains that bioprinting involves us-
ing a computer-guided pipette that takes up cell cul-
tures and “prints” them out in gel layers onto biopa-
per. This biopaper degrades over time; leaving be-
hind the printed structure. According to the Australi-
an Academy of Science (AAS), every tissue in the 
body is naturally made up of different cell types, so 
the required cells are taken from a patient and culti-
vated until there are enough to create cell specific 
‘bio-ink’ that is loaded into the printer. Moreover, the 
AAS explains how these cells seek out similar cells 
to join with much like the way cells in an embryo de-
velop in the womb during embryogenesis, or tissue in 
an adult moves to repair damage. Because the parts 
are synthesized from the organ recipient’s genetic 
matter and precisely match the tissue or organ being 
replaced, CareCloud states that there is less of a 
chance that the immune system will reject the foreign 
tissue. Now that we have covered the basics of sourc-
ing, growing, and implanting bio-prints, let’s talk 
about bioprinting’s potential applications. 
From patient-specific surgical models and 
personalized medicines to replacement body parts 
and custom-made prosthetics, the possibilities of bi-
oprinting are endless. A serious car accident that re-
sults in a passenger’s nose being shattered serves as a 
great example of a situation in which bioprinting can 
be put to use. According to the AAS, bi-
oprinting technology makes it possible to 
reconstruct this nose as a 3D model on the 
computer. A biopsy can simultaneously be 
performed on the patient while cartilage 
cells are extracted from the knee, finger, 
ear or splinters of the shattered nose. The 
cells are reproduced in the laboratory and 
mixed with a biopolymer, which is then 
used to print a new nose to be implanted 
during surgery. In this process, the biopol-
ymer is used as a form of shaping mold 
that is gradually broken down by the body 
and replaced by its own cells. This re-
placement leaves the implant unrecogniza-
ble as it appears cohesive with the individual’s own 
skin and cartilage. Moreover, Futurity forecasts that 
mass-supplied prosthetics are likely to be a thing of 
the past as 3D printing is increasingly used to manu-
facture prosthetics that are tailored to a patient’s anat-
omy and needs. For example, Futurity explains that 
surgeons have to cut a patient’s bone to fit the pros-
thetic in a hip-replacement, but in the future, it will 
be normal to 3D print a prosthetic to fit a patient. Ad-
ditionally, bioprinting has extensive applications in 
the pharmaceutical industry with the potential to 
drastically reduce the need for animal trials in drug 
testing. Cellink contends that this technology offers 
the potential to test treatments for diseases using arti-
ficially affected tissues, eradicating organ donation 
and transplantation. Perhaps bioprinting’s most sig-
nificant application is the use of 3D printed models to 
practice surgical operations. According to Jason 
Chuen, Director of Vascular Surgery at Austin Health 
and a Clinical Fellow at the University of Melbourne, 
studies have shown that operations can be completed 
faster and with less trauma for patients and the poten-
Our Future in a 3-D Printer 
By Ryan Cvelbar 
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tial cost savings alone are considerable. Although 
these ideas sound both exciting and feasible, profes-
sionals have a long way to go until these applications 
become reality.  
Aside from potential applications of bioprint-
ing in the medical field, professionals are currently 
making progress in the development of bioprinting as 
it pertains to some similar applications. “In 2003, 
Wake Forest succeeded in printing the first fully func-
tional mini-kidney, which was able to filter blood and 
produce urine. Since then, scientists have been work-
ing to develop more sophisticated organs like hearts, 
livers and uteruses” (Carecloud). Chuen explains that 
once inside the gel, cells can die in a matter of 
minutes. This isn’t a problem for small structures like 
organoids, an artificially grown organ, that can be 
built quickly and then transferred back into a nutrient 
solution, but it is a problem when attempting to print 
an organ because the initial layers of cells will die be-
fore the organ is completed. Dave Fornell of Diagnos-
tic and Interventional Cardiology argues that the 
Achilles heel of tissue engineering today is the need 
to create vascularity in the structure. He states that the 
key to printing vascularizable micro-organs involves 
chemical modifications of alginate hydrogels to pro-
mote organoid vascularity and suppress inflammatory 
responses. According to Fornell, what we can print 
right now are cardiac patches and small- to medium-
sized blood vessels, skin tissue, soft tissue for recon-
structive surgery, and vascularized micro-organs that 
can be grown in a bioreactor and used to supplement 
the function of a diseased organ like the liver. 
Recent breakthroughs in bioprinting include a 
team from Swansea University’s work that 
has developed a bioprinting process that can create an 
artificial bone matrix in the exact shape of the bone 
required. Mischa explains that, “Over a period of sev-
eral months, the implants fuse with and are eventually 
replaced by a patient’s natural bones with few, if any, 
complications.” The AAS recognizes similar work at 
Wake Forest School of Medicine where researchers 
have successfully designed, built and tested a printer 
that can print skin cells directly onto a burn wound. 
Research engineer Monica Moya from Lawrence Liv-
ermore National Laboratory is also using bioprinting. 
The AAS explains how Moya is using the technology 
to create ‘living’ blood vessels by enabling small 
blood vessels to develop on their own. “Over a period 
of time, the self-assembled capillaries connect with 
the bio-printed tubes, thereby beginning to deliver 
nutrients to the cells on their own—mimicking the 
way these structures work in the human 
body” (science.org). Dr. Anthony Atala, director of 
the Wake Forest Institute for Regenerative Medicine, 
predicts that someday, perhaps in the span of a gener-
ation, you can have a heart made out of your own cell 
tissue. The biotechnology industry is growing at an 
unprecedented rate and the prospects of bioprinting 
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 It is no secret that modern medicine has improved people’s lives in virtually every are of healthcare. 
What is also not a secret is how expensive it is. . Not only does the average American spend roughly $5000 on 
healthcare, they also spend roughly $1200 on pharmaceuticals. The candidates gunning for the U.S. presiden-
cy often bring up the topic of rising pharmaceuticals and what they would do to change it. Medical services 
and products as a whole are of concern for virtually all Americans, and many of them are considered over-
priced. The development of these products isn’t cheap, and it needs funding. On the other hand, citizens would 
rather spend that $1200 on other commodities.  Looking at the path of funding for pharmaceuticals and bio-
medical research as a whole can help people understand why.  
 
 Let’s take a quick look at biomedical research as a whole. Though biomedical research in the United 
States is funded through multiple channels, the largest funder of federal research is the National Institutes of 
Health (NIH). Comprising of 27 institutes and centers in the U.S., it pours over $40 billion into research, 
mainly in the form of grants. These grants are awarded to research institutions, mainly universities and medi-
cal schools, where some of the science is done, and about 10% of funding goes to in-house NIH research. NIH
-funded projects cover a wide range of research areas. Some of their biggest in-house projects include cancer 
research; the National Cancer Institutes budget was $5.098 billion. What’s interesting, however, is that this 
number (just over $40 billion) has remained relatively stagnant over the past two decades and has failed to 
keep up with inflation. As a result, less and less projects are being funded - approximately one in five and less 
research is able to be done.  
 
 Pharmaceutical research, on the other hand, is often done by private firms. These firms both raise mon-
ey and perform the resulting research. For example, The Pharmaceutical Research and Manufacturers of 
America (PhRMA) report that $97 billion was spent in 2017 by biopharmaceutical companies on research and 
development (R&D). This industry alone, then, spends more than double the NIH’s research funding on their 
projects. 
 
 These two areas of healthcare are different in several ways, mainly that pharmaceuticals offer one 
product - drugs - while biomedical firms and institutes offer a variety of services. However, there is another 
key distinction:government institutes like the NIH are, well, publically funded, while private institutes like 
Novartis and Pfizer are for-profit. As much as these firms claim they are trying to save lives, at the end of the 
day they are also trying to maximize their profits and will sell their products at the price the market can bear. 
Unlike the NIH, private firms gather their research funds from their profits, meaning they can only produce 
beneficial drugs as long as they are making a profit. When that stops happening, they either raise prices or 
look for another way to make money.  
 
 The path for funding for biomedical research and pharmaceutical development is a complicated one. It 
has clear advantages: institutions across the country are diligently working to produce innovations, improve-
ments, and efficiencies in the world of medicine. Funding a large number of research programs also results in 
a large number of different and varying ideas. The path isn’t perfect, though. A shrinking NIH budget and in-
creasing pharmaceutical company profits paired with increasing pharmaceutical drug costs are concerning 
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